Carlyle Group (NASDAQ:CG) Stock, Quote.Headers.trade-ideas

Carlyle Group

The Carlyle Group is one of the world's largest alternative-asset managers, with $434.6 billion in total AUM, including $307.3 billion in fee-earning AUM, at the end of June 2024. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure, and natural resources funds (accounting for 34% of fee-earning AUM and 58% of base management fees during 2023), global credit (51% and 27%) and investment solutions (15% and 15%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving more than 2,900 active carry fund investors from 88 countries.

JeffBezos.SeattleSeahawks.Midjourney

Sports

ARES

The NFL will allow private equity funds to buy up to 10% of teams. This could be good news for team owners and bad news for Jeff Bezos.

Jeff Bezos Could Have Competition If He Wants The NFL&#39;s Seattle Seahawks: Private Equity Investments Get League Approval

Pre-market: 5 titoli da monitorare oggi, 13 agosto 2024

Earnings

News

Price Target

Markets

Analyst Ratings

Trading Ideas

Advance Auto Parts Analysts Slash Their Forecasts After Downbeat Earnings

xr:d:DAFkdW1Tf7Y:2,j:2276961543181188932,t:23053105

Equities

Guidance

Asset Sales

Movers

General

Advance Auto Parts&#39; Q2 earnings miss, margin contraction, and revised outlook overshadow the $1.5 billion Worldpac sale.

Advance Auto Parts Q2 Earnings: EPS Miss, Annual Outlook Cut, Sells Worldpac Business

The Carlyle Group Inc

China Green Agriculture, Inc. Common Stock

China Green Agriculture Inc

A2B Australia Ltd DR

The Carlyle Group Inc. - 4.625% Subordinated Notes due 2061

CODE GREEN APPAREL by Code Green Apparel Corp.

Code Green Apparel Corp

CONCORDE GAMING CORP by Concorde Gaming Corp.

Concorde Gaming Corp

CHINA RES GAS UNSP/ADR by China Resources Gas Group Ltd

China Resources Gas Group Ltd

Centerra Gold Inc

X-TR.HAR.CSI CH.S.B.1D ETF

Carlyle Secured Lending, Inc. - Closed End Fund

Carlyle Secured Lending Inc

Carlyle Secured Lending, Inc. - 8.20% Notes due 2028

Capital Group Core Balanced ETF Capital Group Core Balanced ETF

Crown LNG Holdings Limited - Ordinary Shares

Crown LNG Holdings Ltd

Canopy Growth Corporation - Common Shares

Canopy Growth Corp

Capital Group Fixed Income ETF Trust Capital Group Core Bond ETF

CENTRAL GLASS CO LTD ORD by Central Glass Co., Ltd.

Central Glass Co Ltd

COMMERCE GROUP CORP by Commerce Group Corp.

Commerce Group Corp

Capital Group Core Plus Income ETF Capital Group Core Plus Income ETF

Capital Group Conservative Equity ETF Capital Group Conservative Equity ETF

CARLIN GOLD CORP NEW by Carlin Gold Corp.

Carlin Gold Corp

Capital Group Dividend Growers ETF Capital Group Dividend Growers ETF

CHINA GROWTH DEV INC by China Growth Development, Inc.

CONROY GOLD & NATURAL RES by CONROY GOLD AND NATURAL RESOURES PLC

Conroy Gold and Natural Resources PLC

Capital Group Dividend Value ETF Capital Group Dividend Value ETF

Xali Gold Corp

COGECO COMMUNICATIONS ORD by Cogeco Communications Inc

Cogeco Communications Inc

Cogeco Inc

CGN NEW ENERGY HLDGS LTD by CGN New Energy Holdings Ltd

CGN New Energy Holdings Co Ltd

CGE Energy Inc

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics Inc

Capgemini SE

Compugen Ltd

CF Energy Corp

CHUGIN FINL GROUP INC by CHUGIN FINL GROUP INC.

ChainGuardians

Capital Group Global Equity ETF Capital Group Global Equity ETF

Coats Group PLC

Capital Group Global Growth Equity ETF Capital Group Global Growth Equity ETF

Capital Group Growth ETF Capital Group Growth ETF

Viridien ADR

Viridien

CAPITAL GROUP HLDGS INC by Capital Group Holdings, Inc.

Capital Group Holdings Inc

CHAARAT GOLD HLDGS LTD by CHAARAT GOLD HOLDINGS LIMITED

CHINA GAS HLDGS LTD ADR by China Gas Holdings Ltd.

China Gas Holdings Ltd

Capital Group Fixed Income ETF Trust Capital Group Municipal High-Income ETF

CHINA GAS HLDGS LTD ORD by China Gas Holdings Ltd.

CI GLBL HGH YLD CR PR PL HDG SRS ETF

Capital Group Fixed Income ETF Trust Capital Group International Bond ETF (USD-Hedged)

Capital Group International Core Equity ETF Capital Group International Core Equity ETF

Capital Group International Equity ETF Capital Group International Equity ETF

Chemtrade Logistics Income Fund

CI GLOBAL INVSTMNT GRD SER UNT ETF

Celadon Group Inc

ESR LOGOS REIT

CARGOJET INC VARIABLE VTG by Cargojet, Inc.

Cargojet Inc

CHUGOKU ELEC POWER CO by Chugoku Electric Power Company

Chugoku Electric Power Co Inc

CHUGOKU ELEC PWR UNSP/ADR by Chugoku Electric Power Company

CITIGROUP KOREA INC GDR by Citigroup Korea, Inc.

Cassiar Gold Corp

Buscar Co

Coro Global Inc

CHINA MINSHENG BKNG ORD by China Minsheng Banking Corp., Ltd.

China Minsheng Banking Corp Ltd

CHALICE MINING LTD by Chalice Mining Ltd.

Chalice Mining Ltd

Capital Group Fixed Income ETF Trust Capital Group U.S. Multi-Sector Income ETF

Capital Group Fixed Income ETF Trust Capital Group Municipal Income ETF

Capital Group New Geography Equity ETF Capital Group New Geography Equity ETF

CARDIOGENICS HLDGS INC by CardioGenics Holdings Inc.

CardioGenics Holdings Inc

CGN MINING CO LTD by CGN MINING COMPANY LTD.

CGN Mining Co Ltd

COGNETIVITY NEUROSCIENCES by Cognetivity Neurosciences Ltd.

Cognetivity Neurosciences Ltd

Cognyte Software Ltd

CGN Power Co Ltd

Cognex Corp

Calamos Global Total Return Fund - Closed End Fund

Calamos Global Total Return Fund

Contact Gold Corp

CG Oncology Inc

GRAND PHARMACEUTICAL GRP by GRAND PHARMACEUTICAL GROUP LIMITED

Grand Pharmaceutical Group Ltd

C&C Group PLC

CGROWTH CAPITAL INC by CGrowth Capital, Inc.

CGrowth Capital Inc

CI GLOBAL GREEN BOND UNT ETF

GRD Biotechnology Acquisition Limited

CANADIAN GENL INVTS LTD by Canadian General Investments, Limited

CI GLOBAL STNBL INFR FD UNT ETF

WIIM

ALLY

BBVA

CRBG

LPLA

UPST

Shares of companies in the broader financial services and banking sectors are trading higher amid overall market strength following the Fed's rate cut, which could drive a rise in spending and lending demand.

Global investment firm Carlyle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) today announced a strategic investment into North Bridge ESG LLC ("North Bridge"), a leading provider of real estate finance solutions, and a commitment to provide up to $1 billion to facilitate the origination of commercial property assessed clean energy (C-PACE) loans by North Bridge. This partnership leverages Carlyle's strategic growth, real estate, and asset-backed finance expertise and enables North Bridge to address evolving market needs on a larger scale.
North Bridge provides C-PACE financing to institutional borrowers in major markets nationwide. C-PACE is a fixed-rate form of financing secured by local property assessments. As a private credit solution with flexible terms, C-PACE is increasingly sought after for its accretive benefits to commercial real estate capital stacks. The financing can be used for new construction projects, renovations, acquisitions, and retroactively for recapitalization opportunities.

Contracts

Carlyle And North Bridge Announce Strategic Partnership To Provide Up To $1B In C-PACE Financing, The Origination Of Commercial Property Assessed Clean Energy Loans By North Bridge

12 analysts have shared their evaluations of Carlyle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Carlyle Group, presenting an average target of $48.58, a high estimate of $64.00, and a low estimate of $41.00. A decline of 2.65% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1726149842_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive Carlyle Group is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$42.00</td>
<td>-</td>
</tr>
<tr>
<td>Nicholas Watts</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Buy</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$53.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Bill Kirk</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$42.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$46.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Chris Kotowski</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$64.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$44.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$46.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$51.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Brent Dilts</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$44.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Bill Kirk</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$41.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Carlyle Group. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Carlyle Group compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Carlyle Group's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Carlyle Group's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Carlyle Group analyst ratings.</a>
<h2>About Carlyle Group</h2>
The Carlyle Group is one of the world's largest alternative-asset managers, with $434.6 billion in total AUM, including $307.3 billion in fee-earning AUM, at the end of June 2024. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure, and natural resources funds (accounting for 34% of fee-earning AUM and 58% of base management fees during 2023), global credit (51% and 27%) and investment solutions (15% and 15%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving more than 2,900 active carry fund investors from 88 countries.
<h3>A Deep Dive into Carlyle Group's Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Carlyle Group's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 68.82%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Carlyle Group's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 20.08%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Carlyle Group's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.93%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.69%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Carlyle Group's debt-to-equity ratio stands notably higher than the industry average, reaching 2.1. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Carlyle Group: 12 Analysts Share Their Views

Wells Fargo analyst Michael Brown initiates coverage on Carlyle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) with a Equal-Weight rating and announces Price Target of $42.

Initiation

Wells Fargo Initiates Coverage On Carlyle Group with Equal-Weight Rating, Announces Price Target of $42

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Financials sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>COF</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$145.00</td>
<td>$49.6K</td>
<td>3.3K</td>
<td>4.6K</td>
</tr>
<tr>
<td>JPM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$200.00</td>
<td>$28.0K</td>
<td>5.5K</td>
<td>1.1K</td>
</tr>
<tr>
<td>NBTB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$45.00</td>
<td>$240.0K</td>
<td>137</td>
<td>1.0K</td>
</tr>
<tr>
<td>C</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/17/26</td>
<td>$45.00</td>
<td>$61.2K</td>
<td>82</td>
<td>721</td>
</tr>
<tr>
<td>AXP</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/13/24</td>
<td>$240.00</td>
<td>$27.7K</td>
<td>25</td>
<td>519</td>
</tr>
<tr>
<td>CG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$42.50</td>
<td>$70.7K</td>
<td>2.4K</td>
<td>363</td>
</tr>
<tr>
<td>GS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$460.00</td>
<td>$26.7K</td>
<td>469</td>
<td>165</td>
</tr>
<tr>
<td>COIN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$190.00</td>
<td>$28.3K</td>
<td>1.8K</td>
<td>67</td>
</tr>
<tr>
<td>FI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$155.00</td>
<td>$30.7K</td>
<td>129</td>
<td>15</td>
</tr>
<tr>
<td>FCNCA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1420.00</td>
<td>$43.7K</td>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding COF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>), we observe a call option sweep with neutral sentiment. It expires in 38 day(s) on October 18, 2024. Parties traded 234 contract(s) at a $145.00 strike. This particular call needed to be split into 13 different trades to become filled. The total cost received by the writing party (or parties) was $49.6K, with a price of $212.0 per contract. There were 3395 open contracts at this strike prior to today, and today 4612 contract(s) were bought and sold. 
• Regarding JPM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), we observe a put option sweep with bearish sentiment. It expires in 38 day(s) on October 18, 2024. Parties traded 46 contract(s) at a $200.00 strike. This particular put needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $28.0K, with a price of $610.0 per contract. There were 5534 open contracts at this strike prior to today, and today 1136 contract(s) were bought and sold. 
• For NBTB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBTB#NASDAQ">NBTB</a>), we notice a call option sweep that happens to be bearish, expiring in 66 day(s) on November 15, 2024. This event was a transfer of 1000 contract(s) at a $45.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $240.0K, with a price of $240.0 per contract. There were 137 open contracts at this strike prior to today, and today 1010 contract(s) were bought and sold. 
• Regarding C (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>), we observe a put option sweep with bullish sentiment. It expires in 675 day(s) on July 17, 2026. Parties traded 180 contract(s) at a $45.00 strike. This particular put needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $61.2K, with a price of $340.0 per contract. There were 82 open contracts at this strike prior to today, and today 721 contract(s) were bought and sold. 
• Regarding AXP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>), we observe a call option trade with neutral sentiment. It expires in 3 day(s) on September 13, 2024. Parties traded 50 contract(s) at a $240.00 strike. The total cost received by the writing party (or parties) was $27.7K, with a price of $555.0 per contract. There were 25 open contracts at this strike prior to today, and today 519 contract(s) were bought and sold. 
• For CG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>), we notice a call option sweep that happens to be bullish, expiring in 192 day(s) on March 21, 2025. This event was a transfer of 363 contract(s) at a $42.50 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $70.7K, with a price of $195.0 per contract. There were 2425 open contracts at this strike prior to today, and today 363 contract(s) were bought and sold. 
• For GS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>), we notice a put option trade that happens to be bullish, expiring in 66 day(s) on November 15, 2024. This event was a transfer of 14 contract(s) at a $460.00 strike. The total cost received by the writing party (or parties) was $26.7K, with a price of $1910.0 per contract. There were 469 open contracts at this strike prior to today, and today 165 contract(s) were bought and sold. 
• For COIN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), we notice a put option trade that happens to be bullish, expiring in 10 day(s) on September 20, 2024. This event was a transfer of 8 contract(s) at a $190.00 strike. The total cost received by the writing party (or parties) was $28.3K, with a price of $3540.0 per contract. There were 1826 open contracts at this strike prior to today, and today 67 contract(s) were bought and sold. 
• For FI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>), we notice a call option sweep that happens to be bullish, expiring in 66 day(s) on November 15, 2024. This event was a transfer of 15 contract(s) at a $155.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $30.7K, with a price of $2050.0 per contract. There were 129 open contracts at this strike prior to today, and today 15 contract(s) were bought and sold. 
• For FCNCA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>), we notice a call option trade that happens to be bullish, expiring in 129 day(s) on January 17, 2025. This event was a transfer of 1 contract(s) at a $1420.00 strike. The total cost received by the writing party (or parties) was $43.7K, with a price of $43750.0 per contract. There were 0 open contracts at this strike prior to today, and today 1 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

COIN

FCNCA

NBTB

10 Financials Stocks With Whale Alerts In Today's Session

ERIE

HOOD

KNSL

KSPI

NCPL

SLQT

SOFI

Shares of companies within the broader financial sector are trading lower amid overall market weakness. Weakness may be due to August's ISM Manufacturing PMI data indicating an economic contraction.

<a href="https://www.bloomberg.com/news/articles/2024-08-30/carlyle-said-to-near-sale-of-sedgwick-stake-to-altas?srnd=homepage-americas" title="https://www.bloomberg.com/news/articles/2024-08-30/carlyle-said-to-near-sale-of-sedgwick-stake-to-altas?srnd=homepage-americas">https://www.bloomberg.com/news/articles/2024-08-30/carlyle-said-to-near-sale-of-sedgwick-stake-to-altas?srnd=homepage-americas</a>

'Carlyle Nears Sale Of Sedgwick Stake To Altas; Deal Could Value Claims Administrator At $13B; Carlyle Bought Majority Of Sedgwick For $6.7B In 2018' - Bloomberg News

The National Football League (NFL) will soon allow private equity companies the opportunity to invest in teams, which could break records for team sales in the future and create competition for billionaires such as Jeff Bezos, who could be <a href="https://www.benzinga.com/m-a/24/08/40495264/jeff-bezos-has-no-plans-to-buy-nbas-boston-celtics-could-nfl-team-ownership-still-be-in-the-cards">eyeing a team purchase.</a>
What Happened: NFL owners approved a measure to allow private equity minority stakes in teams, which the league previously discussed <a href="https://www.benzinga.com/general/sports/24/05/38710804/nfl-rule-could-open-door-for-big-money-investors-will-your-team-go-up-for-sale">earlier this year</a>.
The new approval marks a key change to the league, which previously allowed teams to have limited partners with minority stakes but no investments from institutional investors.
Private equity funds that have league approval can invest in up to 10% ownership of teams. Each fund can hold ownership stakes in up to six NFL franchises. Teams can sell multiple stakes to different funds, but each investment has to be at least 3% and total private equity investment can not be more than 10% of the team, as <a href="https://www.nfl.com/news/nfl-owners-vote-to-allow-private-equity-funds-to-buy-stakes-in-teams">reported </a>by NFL.com.
The initial approved private equity funds are Arctos Partners, Ares Management Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>), Sixth Street and a consortium group that includes Blackstone Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>), Carlyle Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CG#NYSE">CG</a>), CVC, Dynasty Equity and Ludis.
While additional private equity funds could be approved, the new league change does not include the ability for investment from sovereign wealth funds or pension funds.
Private equity funds will be required to hold onto their investment for six years before being able to sell their stake. Each NFL team will also have to have a controlling owner who has at least 30% ownership of the team. Each team also can have no more than 25 total owners.
The news comes ahead of the 2024 NFL season and could be bad news for billionaires looking to buy NFL teams as they go up for sale in the coming months or years.
The Washington Commanders set a North American sports franchise-record with a $6.1 billion sale valuation in 2023. Among the reported interested parties in the team was <a href="https://www.benzinga.com/general/sports/23/04/31790615/jeff-bezos-passing-on-commanders-ownership-could-he-be-eying-a-different-nfl-team">Amazon founder Jeff Bezos</a>.
As Benzinga previously reported, Bezos could now have <a href="https://www.benzinga.com/general/sports/24/07/39621460/jeff-bezos-to-sell-5-billion-in-amazon-shares-could-he-be-raising-cash-for-seattle-seahawks-purcha">his eyes set on the Seattle Seahawks next,</a> a team that will be up for sale soon as part of the instructions from former team owner Paul Allen before his death in 2018.
When the Seahawks come up for sale, Bezos could face a bidding war with private equity investors or the possibility that he can't buy 100% of the team outright. The new rules will mean there are more investors who have the capital to buy a team stake.
NFL Commissioner Roger Goodell noted "This won't change a thing. This is 10% of a team. All it is is a silent position that would allow access to capital for those teams that wish to offer 10% of their team."
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent082824">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: Sports team ownership has been a lucrative business for many over the years with team valuations soaring thanks to new media rights deals and the growth of streaming companies wanting a piece of live sports.
Team valuations for NFL teams range from $4.71 billion (Cincinnati Bengals) to $10.32 billion (Dallas Cowboys), according to a <a href="https://www.sportico.com/feature/nfl-team-values-ranking-list-1234684165/">Sportico </a>report. The league passed the approval with a 31-1 vote with the Bengals the only team voting against the measure.
Sports fans have a limited number of<a href="https://www.benzinga.com/topic/public-sports-teams"> public sports teams </a>in which to invest. The new change could give investors more opportunities to invest in private equity teams that own stakes in teams. 
While this won't give fans a meaningful stake or a vote on team matters and player transactions, it could create more connection with fans and more investment opportunities.
The NFL decision change could come as it allows team owners the ability to bring in capital from their ownership stake that can be used for team or stadium improvements.
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent082824">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
The image was created using artificial intelligence MidJourney.

Jeff Bezos Could Have Competition If He Wants The NFL's Seattle Seahawks: Private Equity Investments Get League Approval

<a href="https://www.bloomberg.com/news/articles/2024-08-27/nfl-owners-set-to-vote-on-letting-private-equity-invest-in-teams?srnd=all">https://www.bloomberg.com/news/articles/2024-08-27/nfl-owners-set-to-vote-on-letting-private-equity-invest-in-teams?srnd=all</a>
&nbsp;
&nbsp;
NFL owners are set to vote on selling stakes in their franchises to private equity, potentially joining a shift by professional sports leagues to attract institutional investors.
The discussion will take place on Tuesday afternoon in a Minneapolis hotel during a special one-day league meeting, according to people familiar with the matter. Barring a last minute change in the schedule, a vote will then follow.
 &nbsp;

Reported Earlier, NFL Owners Set To Vote On Letting Private Equity Invest In Teams; League Approved PE Firms Arctos, Ares & Sixth Street Partners; Firms Could Be Able To Buy 10% Stakes In NFL franchises

Across the recent three months, 11 analysts have shared their insights on Carlyle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $49.18, with a high estimate of $64.00 and a low estimate of $41.00. Experiencing a 1.44% decline, the current average is now lower than the previous average price target of $49.90. 
<img src="https://www.benzinga.com/files/images/story/2024/1724767233_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Carlyle Group among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nicholas Watts</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Buy</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$53.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Bill Kirk</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$42.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$46.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Chris Kotowski</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$64.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$44.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$46.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$51.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Brent Dilts</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$44.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Bill Kirk</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$41.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Carlyle Group. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Carlyle Group compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Carlyle Group's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Carlyle Group's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Carlyle Group analyst ratings.</a>
<h2>Discovering Carlyle Group: A Closer Look</h2>
The Carlyle Group is one of the world's largest alternative-asset managers, with $434.6 billion in total AUM, including $307.3 billion in fee-earning AUM, at the end of June 2024. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure, and natural resources funds (accounting for 34% of fee-earning AUM and 58% of base management fees during 2023), global credit (51% and 27%) and investment solutions (15% and 15%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving more than 2,900 active carry fund investors from 88 countries.
<h3>Unraveling the Financial Story of Carlyle Group</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Carlyle Group displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 68.82%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 20.08%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.93%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Carlyle Group's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.69%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Carlyle Group's debt-to-equity ratio surpasses industry norms, standing at 2.1. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Decoding 11 Analyst Evaluations For Carlyle Group

Redburn Atlantic analyst Nicholas Watts initiates coverage on Carlyle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) with a Buy rating and announces Price Target of $55.

Redburn Atlantic Initiates Coverage On Carlyle Group with Buy Rating, Announces Price Target of $55

Advance Auto Parts Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) reported weak second-quarter earnings and <a href="https://www.benzinga.com/news/earnings/24/08/40504327/advance-auto-parts-q2-earnings-eps-miss-annual-outlook-cut-sells-worldpac-business">slashed FY24 outlook on Thursday.</a>
The company reported earnings per share of 75 cents, missing the street view of $1.07. Quarterly sales of $2.683 billion beat the street view of $2.679 billion.
Advance Auto Parts revised its FY24 outlook, lowering its earnings per share forecast to $2.00 – $2.50 from the previous range of $3.75 – $4.25, which contrasts with the $3.63 estimate. Additionally, the company adjusted its sales projection to $11.15 billion – $11.25 billion, down from $11.30 billion – $11.50 billion, versus the $11.30 billion estimate.
In a separate press release, the company has confirmed a definitive agreement to sell Worldpac, Inc., its automotive parts wholesale distribution business, to funds managed by global investment firm The Carlyle Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) for $1.5 billion in cash.
Advance Auto Parts shares dipped 17.5% to close at $51.10 on Thursday.
These analysts made changes to their price targets on Advance Auto Parts following earnings announcement.
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/602d4a555864de00015b98c5/max-rakhlenko">TD Cowen analyst Max Rakhlenko</a> maintained Advance Auto Parts with a Hold and lowered the price target from $65 to $55. 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="441" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/23091537/image-228-1024x441.png" alt="" class="wp-image-510917" style="width:583px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/23091537/image-228-1024x441.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/23091537/image-228-300x129.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/23091537/image-228-768x331.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/23091537/image-228-1536x662.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/23091537/image-228.png 1792w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5a259df2efacff0001e43834/greg-melich">Evercore ISI Group analyst Greg Melich </a>maintained Advance Auto Parts with an In-Line and cut the price target from $64 to $60. 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="477" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/23091614/image-229-1024x477.png" alt="" class="wp-image-510922" style="width:620px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/23091614/image-229-1024x477.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/23091614/image-229-300x140.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/23091614/image-229-768x358.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/23091614/image-229-1536x715.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/23091614/image-229.png 1782w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Considering buying AAP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="525" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/23091442/image-227-1024x525.png" alt="" class="wp-image-510915" style="width:591px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/23091442/image-227-1024x525.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/23091442/image-227-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/23091442/image-227-768x394.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/23091442/image-227.png 1302w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Advance Auto Parts Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) is facing a scorching sell-off, with shares plummeting in premarket trading, as a disappointing second-quarter earnings miss, a slashed FY24 outlook, and the announcement of its $1.5 billion <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">Worldpac sale shake investor confidence.</a>
The company reported earnings per share of 75 cents, <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">missing the street view of $1.07. </a>Quarterly sales of $2.683 billion <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/b40502870/advance-auto-parts-reports-second-quarter-2024-results" rel="noreferrer noopener">beat the street view of $2.679 billion.</a>
Revenues remained flat, while comparable store sales increased 0.4%. The company&#8217;s gross profit decreased by 2.3%, totaling $1.1 billion. The gross profit margin declined to 41.5% from 42.5% in the previous year&#8217;s second quarter. This drop was mainly due to strategic pricing investments and increased product costs.
Also Read: <a target="_blank" href="https://www.benzinga.com/top-stories/24/06/39235731/advance-auto-parts-probes-potential-cyber-incident-linked-to-snowflake" rel="noreferrer noopener">Advance Auto Parts Probes Potential Cyber Incident Linked To Snowflake</a>
The company&#8217;s operating income was $71.8 million, or 2.7% of net sales, compared with 4.7% in the second quarter of 2023.
On August 7, 2024, the company declared a regular cash dividend of $0.25 per share. This dividend will be paid on October 25 to all common stockholders of record as of October 11.
The company exited the quarter with cash and equivalents worth $479.418 million. Inventories, net totaled $4.903 billion at quarter-end. The company&#8217;s long-term debt at the quarter end stood at $1.787 billion.
Sale Of Worldpac: In a separate press release, the company has confirmed a definitive agreement to sell Worldpac, Inc., its automotive parts wholesale distribution business, to funds managed by global investment firm The Carlyle Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/b40502736/advance-auto-parts-announces-sale-of-worldpac-to-carlyle-for-1-5-billion" rel="noreferrer noopener">for $1.5 billion in cash.</a>
The transaction is anticipated to be finalized by the end of the year. As of the end of the second quarter of 2024, the Worldpac business generated around $2.1 billion in revenue and approximately $100 million in EBITDA over the past twelve months. Advance Auto Parts anticipates net proceeds of about $1.2 billion after accounting for taxes and transaction fees.
Outlook Lowered: Advance Auto Parts has revised its FY24 outlook, lowering its earnings per share forecast to $2.00 &#8211; $2.50 from the previous range of $3.75 &#8211; $4.25, which contrasts with the $3.63 estimate.
Additionally, the company adjusted its sales projection to $11.15 billion &#8211; $11.25 billion, down from $11.30 billion &#8211; $11.50 billion, versus the $11.30 billion estimate.
Price Action: AAP shares are trading lower by 11.2% to $54.99 premarket at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40502979/us-stocks-poised-for-tepid-start-ahead-of-private-sector-activity-data-and-jackson-hole-symposium-a" target="_blank" rel="noreferrer noopener">US Stocks Poised For Tepid Start Ahead Of Private Sector Activity Data And Jackson Hole Symposium: Analyst Says Market Is Focused On Nvidia Earnings And &#8216;Waiting Is The Hardest Part&#8217;</a></li>
</ul>

<ul>
<li>Over the last twelve months, at the end of the&nbsp;second quarter&nbsp;of 2024, the Worldpac business generated approximately&nbsp;$2.1 billion&nbsp;in revenue and approximately&nbsp;$100 million&nbsp;in EBITDA.</li>
<li>Advance expects net proceeds of approximately&nbsp;$1.2 billion&nbsp;after taxes and transaction fees.</li>
</ul>

Advance Auto Parts Enters Definitive Deal To Sell Worldpac To Funds Managed By Carlyle For $1.5B In Cash

Global investment firm Carlyle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) today announced it has agreed to invest in SEIDOR, a leading technology services and solutions consultancy. The terms of the transaction were not disclosed.
Founded in 1982, SEIDOR provides IT solutions and a variety of services including consulting, implementation, and maintenance across Artificial Intelligence, Microsoft Edge, Customer &amp; Employee Experience, Data &amp; Cloud, Cybersecurity, and enterprise resource planning ("ERP") software. In addition to a highly diversified customer base, the company has partnerships with a range of industry players including SAP, Salesforce, Microsoft, IBM, Google, and AWS, and also develops proprietary products. Headquartered in Barcelona, the company has over 9,000 employees.
Carlyle will aim to support SEIDOR's growth by strengthening the management team, investing in product innovation and expansion, further developing its partnership ecosystem, evolving the company's go-to-market strategy, and driving operational efficiencies by removing business silos and pursuing cross-selling opportunities.
Equity for the investment will be provided by Carlyle Europe Technology Partners ("CETP") V, a €3 billion fund which invests in technology companies across Europe. Carlyle will leverage its longstanding track record of internationalising European software companies, including current portfolio companies GBTEC, SER Group, Shopware, CSS, 1E, Phrase and Hack The Box.

Carlyle Backs SEIDOR's Expansion with €3B Investment Strategy

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>Tencent Music Entertainment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TME#NYSE">TME</a>) shares dipped 18.18% after the company reported a <a href="https://www.benzinga.com//node/40333133" target="_blank" rel="noreferrer noopener">second-quarter revenue miss</a>. Several analysts cut <a href="https://www.benzinga.com//node/40333133" target="_blank" rel="noreferrer noopener">the price target on the stock</a>.</li>
<li>Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) stock fell 5.92% last week. RBC Capital lowered its price target on the stock <a href="https://www.benzinga.com/quote/mbly/analyst-ratings" target="_blank" rel="noreferrer noopener">from $34 to $24</a>.</li>
<li>Rivian Automotive Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) stock declined 5.37% after it reportedly halted production of the electric commercial van it makes for Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) due to a parts deficit in the latest supply chain chaos.</li>
<li>Chipotle Mexican Grill, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) stock decreased 4.87% after the company announced that Chairman and CEO Brian Niccol <a href="https://www.benzinga.com//node/40376234" target="_blank" rel="noreferrer noopener">would be leaving.</a> Several analysts revised ratings and <a href="https://www.benzinga.com//node/40367589" target="_blank" rel="noreferrer noopener">price targets on the stock</a>.</li>
<li>Lineage Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINE#NASDAQ">LINE</a>) stock lost 4.08% in the last week.</li>
<li>Sirius XM Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>) stock fell 3.85% last week after gaining earlier in the week on reports of Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) increasing its stake in the company.</li>
<li>Hershey Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) stock lost 3.23% after Goldman Sachs issued a <a href="https://www.benzinga.com//node/40321537" target="_blank" rel="noreferrer noopener">Sell rating and</a> a price target of $185 on the stock.</li>
<li>Baxter International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) shares were down 2.80% after the company announced a <a href="https://www.benzinga.com//node/40342215">definitive agreement to divest</a> its Vantive Kidney Care segment to Carlyle Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) for $3.8 billion.</li>
<li>Broadridge Financial Solutions Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BR#NYSE">BR</a>) declined 2.76%.</li>
<li>United Therapeutics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) shares decreased 2.38%.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/08/40431642/nvidia-starbucks-and-dell-are-among-top-10-large-cap-gainers-last-week-aug-11-aug-17-are-the-other" target="_blank" rel="noreferrer noopener">NVIDIA, Starbucks And Dell Are Among Top 10 Large Cap Gainers Last Week (Aug 11-Aug 17): Are The Others In Your Portfolio?</a></li>
</ul>
Photo courtesy Rivian

Large Cap

AMZN

LINE

MBLY

RIVN

SIRI

UTHR

Rivian, Chipotle Mexican And Sirius XM Are Among Top 10 Large Cap Losers Last Week (Aug 11-Aug 17): Are The Others In Your Portfolio?

Carlyle Group's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CG#NYSE">CG</a>) short percent of float has fallen 8.59% since its last report. The company recently reported that it has 16.92 million shares sold short, which is 7.77% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.21 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Carlyle Group Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1723826711_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Carlyle Group has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Carlyle Group's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Carlyle Group's peer group average for short interest as a percentage of float is 3.09%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Carlyle Group?

Deutsche Bank analyst Brian Bedell maintains Carlyle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) with a Buy and lowers the price target from $55 to $53.

Deutsche Bank Maintains Buy on Carlyle Group, Lowers Price Target to $53

On Tuesday, Baxter International Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) agreed to sell its Kidney Care segment, Vantive, <a href="https://www.benzinga.com/markets/equities/24/07/39663935/carlyle-eyes-4b-acquisition-of-baxters-kidney-care-unit-vantive-report" target="_blank" rel="noreferrer noopener">for $3.8 billion</a> to The Carlyle Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>)
Baxter will receive approximately $3.5 billion in cash, with net after-tax proceeds currently estimated <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/b40333262/baxter-announces-definitive-agreement-to-divest-its-vantive-kidney-care-segment-to-carlyle-for-3-8" rel="noreferrer noopener">at approximately $3 billion</a>.
Baxter announced its intention to create a standalone kidney care company in January 2023 as part of its broader strategic realignment designed to enhance future performance and create value for all stakeholders.
In March 2024, Baxter announced that it was in discussions to explore a <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/07/39941094/carlyles-4b-purchase-of-baxters-kidney-division-backed-by-ares-and-hps-financing" rel="noreferrer noopener">potential sale of the segment</a>.
Vantive offers products and services for peritoneal dialysis, hemodialysis, and organ support therapies, including continuous renal replacement therapy.
The business has more than 23,000 employees globally and had 2023 revenues of $4.5 billion.
The transaction is expected to close in late 2024 or early 2025.
Following the completion of the pending sale of Kidney Care, Baxter is targeting operational sales <a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40191263/baxter-lifts-annual-outlook-after-strong-q2-beat-medical-devices-sales" rel="noreferrer noopener">growth of 4% to 5% annually</a>.
For 2025, the company anticipates an adjusted operating margin&nbsp;of approximately 16.5% on a continuing operations basis, which reflects an anticipated 100-basis-point negative impact due to stranded costs and the manufacturing supply agreement Baxter will enter into upon the completion of the divestiture of the Kidney Care segment.
Baxter will continue prioritizing capital allocation and expects to direct investments toward higher-growth, higher-return opportunities to drive incremental value.
To support these efforts, Baxter will focus on deleveraging and expects to achieve its investment-grade target of a debt-to-equity ratio below 3.0x by the end of 2025. This goal will be supported by using proceeds from the sale of its Kidney Care segment to repay outstanding debt, including its new bridge facility.
Price Action: BAX stock is down 6.9% at $34.37 at last check Tuesday. The stock initially gained following the announcement but has since reversed.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/08/40339633/marriott-pursues-damages-from-franchisee-for-unauthorized-hotel-use-as-migrant-shelter" target="_blank" rel="noreferrer noopener">Marriott Pursues Damages From Franchisee For Unauthorized Hotel Use As Migrant Shelter</a></li>
</ul>
Photo: Shutterstock

Health Care

Baxter Seals $3.8B Deal With Carlyle For Its Kidney Care Segment

Carlyle To Acquire Baxter's Kidney Care Segment, To Be Named Vantive, For $3.8B

NFL greenlights private equity stakes in teams for the first time

The medtech industry's long-term growth is fueled by growing demand for medical devices, adoption of cutting-edge technologies, and improved efficiency. Thus, it could be ideal to buy fundamentally solid medtech stocks Baxter International (BAX), Zimmer Biomet Holdings (ZBH), and Embecta (EMBC) poised for substantial growth. Keep reading... The integration of AI in healthcare is continuously transforming the operations and processes of the medical field. Companies engaged in the healthcare industry are leveraging artificial intelligence (AI) to advance patients' care and lower costs propelling the medical technology market.
Amid this backdrop, investors could consider investing in sound medtech stocks Baxter International Inc. (<a href="https://stocknews.com/stock/BAX/">BAX</a>), Zimmer Biomet Holdings, Inc. (<a href="https://stocknews.com/stock/ZBH/">ZBH</a>), and Embecta Corp. (<a href="https://stocknews.com/stock/EMBC/">EMBC</a>) which are poised for high-growth.
Technology has revolutionized the healthcare segment with cutting-edge devices and innovations resulting in enhanced outcomes, lower costs, and improved access to care. These innovations led to <a href="https://www.marketsandmarkets.com/blog/HC/The-Global-MedTech-Industry-Outlook-2024#:~:text=The%20global%20MedTech%20sales%20are,to%20outgrow%20the%20US%20market.">FDA approvals of 171 artificial intelligence and machine learning</a> (AI/ML)-enabled medical devices for human use. Also, Generative AI and AI-enabled devices in medtech will remain in focus this year.
The medical technology market revenue is projected to reach $598.90 billion in 2024 worldwide with medical devices market likely to dominate. The medical technology market is <a href="https://www.statista.com/outlook/hmo/medical-technology/worldwide">expected to grow at a CAGR of 5.3%</a>, resulting in a market volume of $775.80 billion by 2029. The US is poised to generate highest revenue of $210 billion by 2024 due to increased investment in R&amp;D.
Further, with AI driving innovation in diagnostics, personalized care, and operational efficiency, the <a href="https://www.medicaldevice-network.com/data-insights/artificial-intelligence-in-medical/?cf-view">artificial intelligence in the medical device industry</a> is flourishing. Medical companies are increasingly adopting AI technologies to enhance their operations and patient care. The market is poised to grow to $97.07 billion by 2028, growing at a <a href="https://blog.marketresearch.com/artificial-intelligence-in-medical-devices-market-set-for-unprecedented-growth">CAGR of 44.4%</a>.
Given these favorable market trends, let's look at the fundamentals of the top three <a href="https://stocknews.com/category/medical-devices-equipment/">Medical – Devices &amp; Equipment</a> stocks, beginning with the third choice.
Stock #3: Baxter International Inc. (<a href="https://stocknews.com/stock/BAX/">BAX</a>)
BAX develops and provides a portfolio of healthcare products worldwide. The company operates in four segments: Medical Products and Therapies; Healthcare Systems and Technologies; Pharmaceuticals; and Kidney Care.
On August 13, BAX and funds managed by global investment firm Carlyle (<a href="https://stocknews.com/stock/CG/">CG</a>) signed a definitive agreement under which Carlyle will acquire BAX's Kidney Care segment, to be named Vantive, for $3.80 billion.
The transaction marks a key milestone in BAX's ongoing business transformation, allowing heightened strategic clarity, operational efficiency and innovation. It also provides increased flexibility to deploy capital toward opportunities to accelerate Baxter's and Vantive's respective growth objectives
On July 30, BAX launched the Helion Integrated Surgical System in Thailand. With the help of operating room integration and cutting-edge technology, Helion simplifies operating rooms to help healthcare institutions in Thailand boost OR efficiency and keeping surgical teams focused and connected.
BAX's <a href="https://www.investopedia.com/terms/n/netsales.asp">net sales</a> increased 2.8% year-over-year to $3.81 billion for the second quarter that ended June 30, 2024. The company's adjusted operating income grew 6.7% from the year-ago value to $522 million. Adjusted net income attributable to Baxter stockholders and adjusted EPS came in at $345 million and $0.68, indicating growth of 3% year-over-year, respectively.
As per the company guidance, BAX expects sales growth of 4% - 5% and adjusted EPS of $0.77 - $0.79 for the third quarter 2024. Further, for the full fiscal 2024, it expects sales growth of 3% and its adjusted EPS is expected to range between $2.93 and $3.01.
Street expects BAX's revenue and EPS for the third quarter (ending September 2024) to increase 3.6% and 14.1% year-over-year to $3.84 billion and $0.78, respectively. Moreover, the company topped the consensus revenue and EPS estimates in all four trailing quarters, which is impressive.
BAX's stock has increased 6.4% over the past month to close the last trading session at $37.54.
BAX's bright prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
The stock has an A grade for Growth and a B grade for Value. Within the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical – Devices &amp; Equipment</a> industry, BAX is ranked #27 out of 135 stocks.
<a href="https://stocknews.com/stock/BAX/">Click here</a> to access additional ratings of BAX for Momentum, Sentiment, Quality, and Stability.
Stock #2: Zimmer Biomet Holdings, Inc. (<a href="https://stocknews.com/stock/ZBH/">ZBH</a>)
ZBH operates as a medical technology company globally. The company designs, manufactures, and markets orthopedic reconstructive products, like knee and hip products, S.E.T. products, and craniomaxillofacial and thoracic products.
On August 7, ZBH signed a definitive agreement to acquire OrthoGrid Systems, Inc., a privately-held medical technology company focused on AI-driven surgical guidance systems for total hip replacement. The acquisition includes OrthoGrid's AI-powered, fluoroscopy-based surgical assistance platform Hip AI&#xAE;, and its FDA-cleared orthopedic applications and over 40 patents.
The strategic acquisition will expand ZBH's hip portfolio with artificial intelligence-driven surgical guidance system.
On June 12, ZBH and RevelAi Health entered into a multi-year co-marketing agreement to commercialize generative AI-powered engagement solutions to advance value-based orthopedic care and health equity. Under the agreement, ZBH Biomet will commercialize RevelAi Health's patient care-management platform, care team dashboard for providers, and any future products or services.
ZBH's revenue and EBITDA have grown at respective CAGRs of 0.7% and 3.3% over the past three years. The company's EBIT has increased 6.3% over the same timeframe, while its net income and EPS have improved at CAGRs of 2.9% and 3%, respectively.
During the second quarter that ended on June 30, 2024, ZBH's net sales increased 3.9% year-over-year to $1.94 billion, and its adjusted gross profit increased 3.3% year-over-year to $1.39 billion. The company's adjusted operating profit grew 7.4% from the year-ago value to $552.60 million.
In addition, net earnings of ZBH and EPS came in at $242.80 million and $1.18, reflecting increases of 15.8% and 18% from the prior year's quarter, respectively.
As per the company guidance for the full year 2024, ZBH expects revenue change of 4.0% - 5.0% and its adjusted EPS is expected between $8 and $8.15.
Analysts expect ZBH's revenue for the third quarter (ending September 2024) to grow 4.7% year-over-year to $1.84 billion and its EPS for the same period is expected to increase 9.3% year-over-year to $1.80. Furthermore, the company surpassed the consensus EPS and revenue estimates in each of the trailing four quarters.
ZBH's shares have gained 4.7% over the past month and marginally over the past year to close the last trading session at $115.05.
ZBH's sound fundamentals are reflected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
The stock has a B grade for Value, Growth, and Quality. Within the Medical – Devices &amp; Equipment industry, ZBH is ranked #24 out of 135 stocks.
In addition to the POWR Ratings we've stated above, we also have ZBH ratings for Stability, Momentum, and Sentiment. Get all ZBH ratings <a href="https://stocknews.com/stock/ZBH/">here</a>.
Stock #1: Embecta Corp. (<a href="https://stocknews.com/stock/EMBC/">EMBC</a>)
EMBC is a medical device company which focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. The company's portfolio include pen needles, syringes, and safety injection devices, and digital applications to assist people with managing patient's diabetes.
On August 9, EMBC's Board of Directors declared a quarterly cash dividend of $0.15 for each issued and outstanding share of its common stock. The dividend is payable on September 13, 2024 to stockholders of record at the close of business on August 27, 2024.
EMBC pays an annual dividend of $0.60, which translates to a yield of 4.29% at the current share price. Its four-year average dividend yield is 2.33%.
EMBC reported revenues of $272.50 million for the third quarter that ended June 30, 2024, and its adjusted gross profit grew marginally from the year-ago value to $190.30 million. The company's adjusted operating income of $83.30 million indicates a growth of 4.4% from the prior year's quarter.
Furthermore, the company's adjusted net income came in at $43 million and $0.74 per share, up 8% and 7.2% year-over-year, respectively.
As per the company's fiscal year 2024 outlook, EMBC expects its revenues between $1.11 billion and $1.12 billion. The company also revised its adjusted EPS to range from $2.30 to $2.35, compared to the previous guidance of $2.20 - $2.30.
Street expects EMBC's revenue for the fiscal year 2024 (ending September 2025) to increase marginally year-over-year to $1.12 billion and its EPS for the same year is expected to be $2.26. Also, the company has topped the consensus revenue and EPS estimate in all four trailing quarters, which is remarkable.
Shares of EMBC have surged 7.8% over the past three months to close the last trading session at $14.
EMBC's POWR Ratings reflect its sound fundamentals. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
EMBC has an A grade for Value and Quality. It also has a B for Growth. The stock has topped among the 135 stocks in the same industry.
In addition to the POWR Ratings we've stated above, we also have EMBC ratings for Sentiment, Momentum, and Stability. Get all EMBC ratings <a href="https://stocknews.com/stock/EMBC/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
ZBH shares were trading at $115.26 per share on Monday afternoon, up $0.21 (+0.18%). Year-to-date, ZBH has declined -4.90%, versus a 18.55% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/zbh-bax-embc-cg-3-high-growth-medtech-stocks-to-buy/>3 High-Growth MedTech Stocks to Buy</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Carlyle Group

Carlyle Group (CG) Forecast

Carlyle Group (NASDAQ:CG) Stock, Quote.Headers.trade-ideas